Osteoporosis and sarcopenia in older age by Edwards, M.H. et al.
  	

Osteoporosis and Sarcopenia in Older Age




To appear in: Bone
Received date: 9 January 2015
Revised date: 19 March 2015
Accepted date: 7 April 2015
Please cite this article as: Edwards MH, Dennison EM, Sayer A. Aihie, Field-
ing R, Cooper C, Osteoporosis and Sarcopenia in Older Age, Bone (2015), doi:
10.1016/j.bone.2015.04.016
This is a PDF ﬁle of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its ﬁnal form. Please note that during the production process
errors may be discovered which could aﬀect the content, and all legal disclaimers that





















1 MRC Lifecourse Epidemiology Unit, University of Southampton, UK 
2 Victoria University, Wellington, New Zealand 
3 Nutrition, Exercise Physiology, and Sarcopenia Laboratory, Jean Mayer Human Nutrition 
Research Center on Aging at Tufts University, Boston, MA, USA 
4 NIHR Musculoskeletal Biomedical Research Unit, Nuffield Department of Orthopaedics, 
Rheumatology and Musculoskeletal Science, University of Oxford, Oxford OX3 5UG, UK. 
5 NIHR Nutrition Biomedical Research Centre, University of Southampton and University 














Correspondence and reprint requests to: 
Prof Cyrus Cooper, MRC Lifecourse Epidemiology Unit, Southampton General Hospital, 
Tremona Road, Southampton, SO16 6YD, UK 
Telephone 023 8077 7624 Fax 023 8070 4021 email: cc@mrc.soton.ac.uk 
 
Keywords 
Osteoporosis, Sarcopenia, Bone, Muscle, Epidemiology, Definition. 
Abstract 
Osteoporosis and sarcopenia are common in older age and associated with significant 
morbidity and mortality.  Consequently, they are both attended by a considerable 
socioeconomic burden.  Osteoporosis was defined by the World Health Organisation (WHO) 
in 1994 as a bone mineral density of less than 2.5 standard deviations below the sex-specific 
young adult mean and this characterisation has been adopted globally.  Subsequently, a 
further step forward was taken when bone mineral density was incorporated into fracture risk 
prediction algorithms, such as the Fracture Risk Assessment Tool (FRAX®) also developed 
by the WHO.  In contrast, for sarcopenia there have been several diagnostic criteria 












and muscle function.   However, none of these have been universally accepted.  This has 
led to difficulties in accurately delineating the burden of disease, exploring geographic 
differences, and recruiting appropriate subjects to clinical trials.  There is also uncertainty 
about how improvement in sarcopenia should be measured in pharmaceutical trials. 
Reasons for these difficulties including the number of facets of muscle health available, e.g. 
mass, strength, function, and performance, and the various clinical outcomes to which 
sarcopenia can be related such as falls, fracture, disability and premature mortality.  It is 
imperative that a universal definition of sarcopenia is reached soon to facilitate greater 








Osteoporosis and sarcopenia are common diseases that predominantly affect older 












to considerable health and social costs [3, 4].  Specially, sarcopenia is associated with 
increased rates of disability, poor mobility, frailty, and hospitalisation [5, 6] and it has been 
estimated that, in the United States, sarcopenia resulted in additional healthcare costs of 
over $18 billion in 2001 [4].  Furthermore, in common with hip and vertebral fracture 
fractures, a decline in muscle health has also been shown to predict future mortality from 
middle-age into later life [7].  Given current secular trends in population demographics with 
greater longevity, the burden of both osteoporosis and sarcopenia may continue to increase. 
 
In addition to the similar population in which they occur, there is also growing evidence of a 
link between the two conditions.  Studies have shown associations between bone and 
muscle health by dual energy x-ray absorptiometry (DXA) and more recently using cross-
sectional imaging techniques [8, 9].  DXA studies have focussed on relationships between 
facets of muscle health and either bone mass or density and have tended to show positive 
relationships [10-12].  The use of peripheral quantitative computed tomography (pQCT) has 
additionally shown bone size and strength to be associated with muscle size, and to a lesser 
extent, muscle strength.  Relationships of muscle with cortical and trabecular volumetric 













There are several potential explanations for these interrelationships (Figure 1).  The 
mechanostat hypothesis describes the action of muscle contraction providing a direct 
mechanical stimulus to bone which promotes osteogenesis [13].  Hormones, such as growth 
hormone, can have positive effects on the growth of muscle and bone [14, 15].  Furthermore, 
exercise and levels of activity clearly augment both of these components of the 
musculoskeletal system.  There are also likely to be common genetic and developmental 
components to muscle and bone health [16, 17].    
 
Despite their similarities and interrelationships, study into these diseases is at very different 
stages of evolution, with research into osteoporosis considerably ahead.  This review 
describes the progress that has been made in defining these conditions and explores the 
reasons for the discrepancy in progress made. 
 
The history of osteoporosis 
Osteoporosis is a skeletal disease characterised by low bone mass and microarchitectural 
deterioration of bone tissue with a consequent increase in bone fragility and susceptibility to 
fracture [18].  The term literally means “porous bone” and was first introduced in France and 












tissue which is normally mineralised but reduced in quantity.  This abnormality is the 
mechanism through which bones become weaker, increasing the risk of fractures occurring. 
 
A significant leap forward was made with the development of non-invasive techniques able 
to assess bone mineral density (BMD) in vivo.  Up to that point, attempts had been made to 
quantify bone health purely using plain radiographs, such as assessments of cortical 
morphometry [19].  Single photon absorptiometry was introduced in the 1960s and was 
subsequently replaced by dual photon absorptiometry.  Both relied on radionuclide sources 
[20] and took over 15 minutes to complete (per site).  The radionuclide decayed and 
consequently had a finite lifespan, needing to be changed at regular intervals.  Around 25 
years ago, the radionuclide source was superseded by an X-ray source and DXA scanners 
were born with faster scanning times and greater spatial resolution.  This technique allows 
measurement of areal bone mineral density (aBMD) primarily at the hip and lumbar spine. 
 
In 1994, the next step change in the definition of osteoporosis occurred, when a working 
group of the World Health Organisation (WHO) used bone density measurements by DXA to 
provide a practical definition of osteoporosis as an aBMD of less than 2.5 standard 












fracture, in order to provide comparability, the subset of women with osteoporosis who had 
also suffered one or more fragility fractures were deemed to have severe (established) 
osteoporosis.  Osteopenia was defined as an aBMD level between 1 and 2.5 SD below the 
young normal mean.   
 
This definition has been adopted throughout the world and has allowed great strides forward 
within this disease area.  Prevalence was compared between different geographical 
locations and this led to hypotheses regarding likely aetiology.  Study participants could be 
more easily selected and beneficial effects on bone could be quantified facilitating research 
into pharmaceutical agents to treat osteoporosis.  This has led to the licensing of several 
medications with good evidence for efficacy in fracture risk reduction. 
 
Overall within a population, higher aBMD is associated with greater bone strength.  
Specifically, it has been shown that there is an almost doubling of fracture risk for every one 
standard deviation reduction in aBMD [22].  However, these measures alone do not explain 
all of the variance in fracture risk.  This is partly related to the inability to measure cortical 
and trabecular bone separately, and to take into consideration the bone’s material quality or 












discrimination using cross-sectional imaging techniques but the incremental gains tend to be 
relatively small [25, 26].  These techniques may however allow better understanding of the 
specific pathogenesis of osteoporosis at the structural level.  In contrast, a considerable 
improvement in fracture prediction has been achieved with the development of fracture risk 
prediction algorithms, such as the Fracture Risk Assessment Tool (FRAX®). 
 
FRAX® uses clinically available risk factors, with or without aBMD, to determine an 
individual’s risk of major osteoporotic fracture and hip fracture in the next 10 years [27].  As 
this is more accurate than using aBMD alone, it allows better targeting of treatments to those 
at greatest risk with positive effects on the ratio of risk to benefit.  Therefore, we are now at a 
point where we can evaluate whether or not to treat an individual and have several effective 
therapies to do so, with more in the pipeline. 
 
The history of sarcopenia 
The term sarcopenia was first coined in 1989 by Irwin Rosenberg who used it to pertain to 
the loss of muscle mass with age [28, 29].  It has since become apparent that muscle 
function, in addition to muscle mass, is necessary to describe sarcopenia and so the 












be thought to be the central factor, it is only weakly associated with function and disability.  It 
does, however, relate to low muscle strength which is strongly associated with these clinical 
outcomes [30].  Furthermore, although both muscle mass and muscle function decline from 
the age of 35 years [31], muscle strength and power decrease more rapidly than muscle 
mass [32] implying that they may be more sensitive to the changes that are occurring.    
  
Several consensus definitions have been proposed to define sarcopenia clinically [33-35], 
most recently from the Foundation of the National Institute of Health (FNIH) sarcopenia 
project [30].  Although they all differ to some extent, each includes a measurement of both 
muscle size and muscle function.   The assessment of muscle size utilised in the European 
Working Group on Sarcopenia in Older People (EWGSOP) and International Working Group 
on Sarcopenia (IWGS) definitions is that of skeletal mass index (appendicular mass relative 
to height squared) [33, 34].  This mitigates against defining individuals as sarcopenic or not 
based solely on their size.   In contrast, the FNIH definition recommends use of muscle mass 
relative to body mass index (BMI) focussing more on the importance of adequate muscle for 
a given level of adiposity [30].  This is in keeping with the concept of sarcopenic obesity 












and excess adiposity.  This combination is important as there is evidence that it may 
adversely affect health to a greater extent than either condition alone [36].  
 
Muscle mass cut points have been suggested for each of the definitions.  In the IWGS 
definition it equates to an appendicular lean mass divided by height squared of <7.23kg/m2 
in men and <5.67kg/m2 in women [34].  The EWGSOP offers several DXA cut points all of 
which are of a similar magnitude [33].  From their large observational dataset, the FNIH 
definition suggests cut offs of appendicular lean mass over BMI of <0.789 for men and 
<0.512 in women, both of which predicted impaired mobility as assessed by a gait speed of 
<0.8 m/s [30].   
 
Usual gait speed is the measure of muscle function in both the IWGS and ESPEN SIG 
definitions and this can be assessed using a 4 metre walk test.  Interestingly, the cut offs 
differ by study group being <1m/s for the IWGS definition but more stringent at <0.8m/s for 
the ESPEN SIG definition [34, 35].  The EWGSOP definition is similar in that it suggests 
sarcopenia is present with the occurrence of low muscle mass along with low gait speed 
(<0.8m/s) but differs in that the later could be replaced by low muscle strength (grip strength) 












females) alone as the required measure of muscle function [30].  Cut offs were higher in the 
EWGSOP definition and rates of sarcopenia were correspondingly greater [37].   
 
In addition to those measures of muscle function already explored, there are other related 
parameters, such as muscle endurance and levels of habitual activity.  Although both may 
relate to functional ability, they will clearly also be strongly influenced by factors other than 
sarcopenia.  Furthermore, there are few published data concerning these outcomes and a 
lack of consistency in the way they are defined.  Consequently they have not been included 
in current consensus definitions. 
 
Although there are certainly similarities between the four consensus definitions described 
above, the subtle differences result in different groups of individuals being identified as 
sarcopenic [37].  Currently, there is therefore no universally accepted way to determine 
which patients are sarcopenic.  This leads to several difficulties in investigating the condition. 
 
The importance of defining sarcopenia 
As sarcopenia is associated with significant morbidity and is a predictor of premature 












consensus definition of sarcopenia would allow an evaluation of prevalence across different 
geographical areas.  This would allow a more accurate quantification of the burden of 
disease and, as in the case of osteoporosis, potentially provide further clues to the aetiology.  
It would also allow identification of individuals at risk of the disease in order to evaluate its 
natural history and to target treatment where appropriate.  Interventions may include diet, 
exercise and, in the future, pharmaceutical agents.   
 
Furthermore, a universal definition of sarcopenia would also simplify participant selection for 
studies, including those of therapeutic agents, and would likely facilitate regulatory approval.  
In addition, it is also imperative to produce an easily measureable and clinically important 
study outcome.  Options would include change in muscle size, muscle strength, or physical 
performance.  However, as will be discussed, there are benefits and limitations to each of 
these.  Furthermore, in line with fracture risk reduction in osteoporosis, it would also be 
beneficial if a drug could be shown to ameliorate one or more of the adverse clinical 
outcomes of sarcopenia. 
 












When a definition of sarcopenia is developed in clinical practice, it is important that it is 
practical, affordable, and acceptable to patients.  Although it may be possible to use a more 
complicated and expensive method within research, it would be favourable to have a 
definition that could be used in both settings allowing results of studies to be more easily 
translatable into clinical practice. 
 
The principle reason that progress in sarcopenia research has not advanced as rapidly as 
osteoporosis research, is the difficulty in establishing a consensual definition of sarcopenia 
that achieves the objective of a diagnostic criterion, as well as serving as an appropriate 
outcome measure for clinical trials of treatment. It is clear that any definition could use 
various combinations of muscle mass, strength and physical performance. However, the 
extent to which these three measures may be combined in a universal definition remains 
controversial. Some approaches attempt to incorporate all three components (EWGSOP) 
while others focus on simply one measure, such as gait speed.  
 
Another difficulty has been a decision on which measures of muscle mass, strength and 
physical performance are most appropriate.  Which is chosen may depend on what clinical 












associated with mobility and both gait speed and grip strength have been associated with 
several other outcomes including premature death [7].   
 
This question also arises when assessing for clinical improvement.  In osteoporosis, aBMD 
has been universally adopted as a good proxy for bone strength.  Whereas in sarcopenia the 
most appropriate measure is not as apparent.  Each possible endpoint has its own 
advantages and disadvantages (table 1).  Similarly, the important clinical event in 
osteoporosis is obviously fracture.  However, sarcopenia is associated with several adverse 
outcomes including falls, fractures, disability and death.  Choosing the primary clinical 
outcome to include in clinical trials is therefore more problematic.   
 
The move towards a consensus is urgently needed and it may be that the two objectives 
(classification of individuals as disease or non-disease, and an outcome measure for clinical 
trials of novel therapies) require distinct definitional approaches [38]. 
 
Conclusion 
There are many similarities between osteoporosis and sarcopenia including patient 












mechanistic interrelationship between muscle and bone with sarcopenic individuals at 
greater risk of osteoporosis and vice versa.   Although both are well recognised, there is a 
considerable difference in the progress that has been made in managing the two conditions.   
 
A universal definition was established for osteoporosis in 1994 and this has allowed 
thorough assessment of its epidemiology, aetiology and fracture risk assessment, and for 
treatments to be developed.  In contrast, there is still ongoing debate regarding how best to 
define sarcopenia.  Although it tends to be accepted that this should include a measure of 
muscle size and muscle function, the precise nature of these measures and the cut offs to 
be used have not be confirmed. 
 
It is imperative that a definition is agreed on soon to drive forward progress in this field.  A 
better understanding of the prevalence and burden of sarcopenia will potentially build the 
case for further funding and interest from industry.  It will also facilitate appropriate 
recruitment to studies and allow optimal measurement of improvement in muscle health in 













One way to aid in the determination of which definition of sarcopenia should be adopted may 
be to more thoroughly examine their relationships, and those of their individual facets, to 
adverse clinical outcomes such as falls, fracture, disability, and death.  This may allow an 


























Table 1:  Potential endpoints in trials of interventions for sarcopenia and osteoporosis.  
Adapted with permission from Cooper et al. [38]. 
 Advantages Disadvantages 
Sarcopenia 
Muscle mass 1. Specific to skeletal muscle 
2. Responsive to change 
3. Easy to implement with the 
established use of DXA 
1. Not as powerful a predictor of 
physical capability as muscle 
strength or gait speed 
2. Difficult to detect small 
changes using DXA (CT or MRI 
should be used) 
 
Muscle strength 1. Powerful predictor of physical 
capability 
2. Includes a neuromuscular 
component 
3. Good correlation with gait 
speed 
1. Not reflected in the term 
‘sarcopenia’ 
2. Possibly restricted in the 
clinical trial context by 
frequency of visits 
Muscle power 1. Specific to skeletal muscle 
2. Includes a neuromuscular 
component 
3. Strongly predictive of 
functional mobility and risk of 
falls among older adults 
1. Generally requires 
expensive equipment 
 
Muscle fatigue 1. Important determinant of 
force production 
1. Few published data 
2. Lack of definitional consistency 
Osteoporosis   
Bone mineral density 1. Predicts fracture risk 
2. Easily measured by DXA 
3. DXA scanners are widely 
available 
1. Lumbar spine readings 
subject to artefact 
2. Timing of repeat 
measures limited by scan 
precision 
 













2. Associated with 
morbidity and mortality 
may be missed 
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- Osteoporosis has been clearly defined and fracture risk prediction tools allow 
accurate evaluation of the likelihood of adverse outcomes. 
 
- Although several consensus definitions of sarcopenia have been suggested, none 
have been universally adopted. 
 
- A universal definition of sarcopenia is required to facilitate advancement of research 
in this area. 
